Results of GPOH-HD-2003 study in treatment of Hodgkin’s lymphoma in children and adolescents in the Morozovskaya Children’s Clinical Hospital
-
Published:2020-03-02
Issue:1
Volume:7
Page:31-40
-
ISSN:2413-5496
-
Container-title:Russian Journal of Pediatric Hematology and Oncology
-
language:
-
Short-container-title:Ross. ž. det. gematol. onkol.
Author:
Naumova A. S.1ORCID, Tiganova O. A.2ORCID, Ilyenko L. I.3ORCID, Lavrukhin D. B.1, Kondratchik K. L.2ORCID, Baybak O. I.1, Bronin G. O.1, Maltseva M. A.1, Makhmudova G. N.1, Makhortykh T. Zh.1, Mutorova O. Yu.1, Nepokulchitskaya N. V.1, Sapelkina T. S.1, Tomilin I. Ya.1, Fuks O. Yu.1, Shershakova E. A.1
Affiliation:
1. Morozovskaya Children’s Clinical Hospital, Department of Health in Moscow 2. Morozovskaya Children’s Clinical Hospital, Department of Health in Moscow; N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia 3. N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Abstract
Relevance. Hodgkin’s lymphoma (HL) is a rare clonal neoplasm of lymphatic tissue. In the structure of malignant neoplasms in children HL accounts for 4–6 % and for 16 % in adolescents. Now children and adolescents with confirmed histology of HL in the Department of Oncology and Hematology, Morozovskaya Children’s Clinical Hospital, treated with the GPOH-HD-2003 protocol. The authors of the article presented the experience of treatment children and adolescents with HL according to recommendations of GPOH-HD-2003 in the Department of Oncology and Hematology, Morozovskaya Children’s Clinical Hospital.Patients and methods. From January 1, 2003 until December 31, 2018, 62 patients (35 boys, 27 girls) received therapy according to recommendations of GPOH-HD-2003 study. Age of patients ranges from 4.7 to 17.6 years, mean age was 13.3 years. All patients are allocated to three treatment groups (TGs) based on staging, in TG-1 were 2 patients, in TG-2 – 30 patients, in TG-3 – 30 patients. TG-1 patients received two courses of for induction: OEPA for boys and OPPA for girls. TG-2 and TG-3 patients received further two or four cycles COPP (girls) or COPDAC (boys), respectively. After chemotherapy all patients received initially involved-field irradiation with 19.8 Gy.Results. CTCEA grade 1 or 2 hematotoxicity was the most common recorded adverse reaction in the OEPA regimen for boys, grade 3 or 4 hematotoxicity – in the OPPA regimen for girls. Also hematotoxicity was more pronounced with COPP than COPDAC. Overall (OS), event-free (EFS) and relapse-free (RFS) survival rates at 5 years were 100 % for the period of the observation time (the median observation time was 48.12 months). No treatment-related deaths, relapses or second malignancies were recorded during this period.Conclusion. OS, EFS and DFS rates indicates high efficiency and low toxicity of GPOH-HD-2003 study regardless of the initial stage.
Subject
Oncology,Hematology,Pediatrics, Perinatology and Child Health
Reference25 articles.
1. Kaatsch P. Epidemiology of childhood cancer. Cancer Treat Rev 2010;36(4):277–85. doi: 10.1016/j.ctrv.2010.02.003. 2. Arya L., Dinand V. Current Strategies in the Treatment of Childhood Hodgkin’s Disease. Ind Ped 2005;42:1115–28. PMID: 16340052. 3. Hochberg J., Waxman I.M., Kelly K.M., Morris E., Cairo M.S. Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Haematol 2009;144(1):24–40. doi: 10.1111/j.1365-2141.2008.07393.x. 4. Ekstrand B., Horning S. Hodgkin’s Disease. Blood rev 2002;16(2):111–7. doi: 10.1054/blre.2002.0190. 5. Georgakis M.K., Karalexi M.A., Agius D., Antunes L., Bastos J., Coza D., Demetriou A., Dimitrova N., Eser S., Florea M., Ryzhov A., Sekerija M., Žagar T., Zborovskaya A., Zivkovic S., Bouka E., Kanavidis P., Dana H., Hatzipantelis E., Kourti M., Moschovi M., Polychronopoulou S., Stiakaki E., Kantzanou Μ., Pourtsidis A., Petridou E.T. Incidence and time trends of childhood lymphomas: findings from 14 Southern and Eastern European cancer registries and Surveillance, Epidemiology and End Results, USA. Cancer Causes Control 2016;27(11):1381–94. doi: 10.1007/s10552-016-0817-3.
|
|